Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
OtherErratum

Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
Yangling Li
1Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China
2Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dongmei Zhou
1Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuang Xu
1Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingjun Rao
3Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zuoyan Zhang
4School of Medicine, Zhejiang University City College, Hangzhou 310015, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linwen Wu
4School of Medicine, Zhejiang University City College, Hangzhou 310015, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chong Zhang
4School of Medicine, Zhejiang University City College, Hangzhou 310015, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chong Zhang
  • For correspondence: [email protected] [email protected]
Nengming Lin
1Department of Clinical Pharmacology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China
2Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
3Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nengming Lin
  • For correspondence: [email protected] [email protected]
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

In the published paper1, errors appeared in Figure 1D on page 391. In Figure 1D, an incorrect gel image was shown for Bcl-xL in NCI-H1299 cells. Figure 1D has been updated to correct the mistake above. The errors do not affect the conclusions of this article. We apologize for the errors and for any confusion that they may have caused.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

(C) NSCLC cells were treated with harmine at the indicated concentrations for 24 h, and the expression of the indicated proteins were detected by Western blot. (D) NSCLC cells were treated with 20 µM harmine for 1, 3, 6, 9, and 12 h, and the expression of the indicated proteins was detected by Western blot.

  • Received October 29, 2019.
  • Accepted February 3, 2020.
  • Copyright: © 2022, Cancer Biology & Medicine
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Reference

  1. 1.↵
    1. Li Y,
    2. Zhou D,
    3. Xu S,
    4. Rao M,
    5. Zhang Z,
    6. Wu L, et al.
    DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors. Cancer Biol Med. 2020; 17: 387–400.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 19 (7)
Cancer Biology & Medicine
Vol. 19, Issue 7
15 Jul 2022
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang, Nengming Lin
Cancer Biology & Medicine Jul 2022, 19 (7) 1109-1110; DOI: 10.20892/j.issn.2095-3941.2022.0172

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang, Nengming Lin
Cancer Biology & Medicine Jul 2022, 19 (7) 1109-1110; DOI: 10.20892/j.issn.2095-3941.2022.0172
Digg logo Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Reference
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Erratum to A truncated protein product of the germline variant of the DUOX2 gene leads to adenomatous polyposis
  • Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients
Show more Erratum

Similar Articles

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2023 Cancer Biology & Medicine

Powered by HighWire